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Summary. A microdilution assay using Alamar Introduction
Blue, a colorimetric indicator, was compared with
the NCCLS macrodilution broth assay for vori- Voriconazole is a new triazole agent that appears
to have a broader spectrum of antifungal activityconazole, fluconazole, and itraconazole against
Candida albicans, Candida glabrata, and Candida krusei. than the parent compound, fluconazole [1–6].
Prior studies that have assessed the in vitro activityConcordance (±2 dilutions) between the two
methods was highest for voriconazole (98.3%), of voriconazole against Candida species have
utilized the National Committee for Clinicaland for fluconazole and itraconazole it was 94.3
and 95.4%, respectively. Twenty-six of 32 (81.2%) Laboratory Standards (NCCLS) recommended
microdilution or macrodilution methods. How-discordant readings (≥3 dilutions different) were
noted in C. glabrata isolates, and all but two ever, the visual turbidity endpoints of these assays
are frequently difficult to define for azole agents.isolates showing discordance had higher minimum
inhibitory concentration readings with the colori- Several species, most notably Candida albicans, exhi-
bit a trailing phenomenon rather than a sharpmetric method.
end-point [7, 8].
Alamar Blue (AccuMed, Westlake, OH, USA)Zusammenfassung. Ein Mikrodilutionstest un-
ter Verwendung des Farbindikators Alamarblau is an oxidation–reduction colorimetric indicator
that, in the presence of actively growing organisms,wurde mit dem NCCLS-Makrodilutionstest zur
Empfindlichkeitsprüfung von Candida albicans, C. changes colour from a deep blue to a bright
pink. We and others have previously shown theglabrata und C. krusei für Voriconazol, Fluconazol
und Itraconazol verglichen. Die Übereinstimmung feasibility of using this system for antifungal suscep-
tibility testing [9–14]. Voriconazole has not pre-(±2 Verdünnungsstufen) war am besten bei Vori-
conazol (98.3%), gefolgt von Fluconazol (94.3%) viously been tested with this method.
In this study, we compared the results obtainedund Itraconazol (95.4%). Diskordante Ablesungen
(≥3 Verdünnungsstufen) traten 26 mal (81.2%) using a colorimetric microdilution method with
the NCCLS macrodilution method for isolatesbei C. glabrata-Isolaten auf, aber außer zwei zeigten
alle diskordanten Isolate höhere MHK-Werte mit of C. albicans, Candida glabrata and Candida krusei
against voriconazole, as well as fluconazole andder kolorimetrischen Methode.
itraconazole.
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the powder in dimethyl sulfoxide (DMSO). that of the comparison tube that consisted of a
155 dilution of the growth control (80% growthFluconazole (Pfizer, Inc.) was dissolved in sterile
distilled water. Itraconazole ( Janssen Research suppression). Concentrations of fluconazole
ranged from 0.06 to 64 mg ml−1; itraconazole andFoundation, Beerse, Belgium) was solubilized in
DMSO. All stock solutions were stored at −70 °C voriconazole ranged from 0.007 to 4 mg ml−1.
The Alamar Blue modified NCCLS micro-and then thawed and diluted in RPMI-1640
(Sigma, St. Louis, MO, USA) on the day that the dilution method was performed as described pre-
viously [12]. The reagents, medium preparation,test was performed.
inoculum and drug concentrations were the same
as noted above for the macrodilution method
Fungal isolates with two exceptions: Alamar Blue (1 ml of 100×
reagent) was added to each 1 ml of RPMIIsolates of C. albicans, C. glabrata and C. krusei were
obtained between 1981 and 1997 from our patient 1640-MOPS medium prior to inoculation of the
yeast, and U-bottom, 96-well, microtitre platespopulations, including those who had neutropenia
[15, 16] or HIV infection [17] and those who were used for the assay. To each well was added
180 ml of RPMI 1640–MOPS with Alamar Bluewere in an intensive care unit or a nursing home
[18]. The isolates from the 1980s had been stored containing 0.5×103 to 2.5×103 yeast cells and
20 ml of the appropriate concentration of drug.at room temperature in distilled water in air-tight
containers, and the isolates from 1990 onward The plates were incubated at 35 °C for 48 h.
The MIC was determined as the lowest drugwere stored at −70 °C in Sabouraud glucose
broth with glycerol. Each isolate was retrieved concentration that maintained a blue or a blue–p-
ink hue. Wells with growth were pink–red infrom storage and plated twice in succession on
Sabouraud glucose agar prior to testing. Two
control strains, C. glabrata ATCC 90030 and
Candida parapsilosis ATCC 90018, were tested on colour.
each day that the minimum inhibitory concen-
tration (MIC) levels were determined. Results
A total of 137 isolates of C. albicans, 124 isolates
of C. glabrata, and 20 isolates of C. krusei were





results differed byThe NCCLS broth macrodilution method was
performed as outlined in the M27-A document ≤1 dilution for the three triazoles for each of the
three Candida species (Table 1). Major discordance[19]. Briefly, RPMI 1640 medium with morph-
olinepropanesulfonic acid (MOPS) buffer (Sigma), (≥3 dilutions different) between the two methods
occurred on only 32 determinations (Table 2). Thewas used at a final pH of 7.0. The final inoculum
was 0.5×103 to 2.5×103 yeast cells ml−1; the total discordance was most marked for C. glabrata (26
of 32 discordant readings) and with MIC determi-volume was 1 ml. Tubes were incubated at 35 °C
for 48 h. The MIC was the drug concentration at nations for itraconazole and fluconazole. Only
three isolates (all C. albicans) showed major discor-which visual turbidity was less than or equal to
Table 1. Comparison of triazole susceptibilities obtained with NCCLS macrodilution method versus the Alamar Blue microdilution
method















macro 0.007–2 0.01 0.03 0.01–>4 0.06 0.12 0.06–>64 0.25 1
Alamar 0.007–2 0.01 0.06 0.01–>4 0.06 0.12 0.12–32 0.5 1
C. glabrata (124)
macro 0.06–>4 1 2 0.06–>4 1 4 0.5–>64 8 32
Alamar 0.06–>4 1 2 0.25–>4 1 4 2–>64 16 32
C. krusei (20)
macro 0.25–2 0.5 2 0.12–>4 2 4 32–>64 64 >64
Alamar 0.25–2 1 2 0.25–>4 2 4 32–>64 64 >64
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Table 2. Concordance of Alamar Blue colorimetric microdilution method with NCCLS macrodilution method
Organism (no.) Voriconazole Itraconazole Fluconazole
±2 dil ±3 dil ±2 dil ±3 dil ±2 dil ±3 dil
C. albicans (137) 126 (92) 134 (98) 123 (90) 136 (99) 122 (89) 135 (99)
C. glabrata (124) 116 (94) 124 (100) 100 (81) 112 (90) 99 (80) 110 (89)
C. krusei (20) 17 (85) 20 (100) 19 (95) 20 (100) 20 (100) 20 (100)
Results expressed as number (%) of isolates in each dilution range in which MIC values obtained by the colorimetric method were
concordant with those obtained by the NCCLS method.
dance for voriconazole. For 30 of the 32 major easier to read than the turbidity endpoints of the
NCCLS method. However, there were problem-discordant readings, the colorimetric reading
was higher than the NCCLS macrodilution read- atic isolates of C. albicans that showed trailing by
the NCCLS method and that also demonstrateding. For all three triazoles, the colorimetric change
was not completed by 24 h for many isolates, ‘colorimetric trailing’, manifested by mauve hues
rather than discrete red–blue endpoints, by theespecially C. glabrata isolates, which tended to grow
more slowly. By 48 h, the colour changes were Alamar Blue assay.
Recently, Rex et al. in an attempt to correlateclear-cut and able to be read reproducibly. Some,
but not all, isolates that demonstrated trailing and in vitro susceptibility testing with in vivo efficacy in
an animal model, noted that 24-h MIC readingswere difficult to read by the 80% visual turbidity
endpoint also showed gradations of mauve-to- may be more appropriate than 48-h readings
for Candida species [8]. Similarly, Revankar et al.purple, rather than clear-cut red–blue endpoints,
identified several strains that exhibited trailing
and for which 24-h readings matched better with
clinical outcome than 48-h readings [7]. However,by the colorimetric assay.
we and others [14] have found that the colori-
metric readings were not fully developed at 24 h,Discussion
In this study, we found that a colorimetric assay especially for the more slowly growing C. glabrata
isolates. Thus, for 48-h readings, the Alamar Blueutilizing the Alamar Blue reagent was comparable
with the NCCLS macrodilution broth method for colorimetric assay appears to be a useful addition
to yeast susceptibility testing, but 24-h endpointsvoriconazole, as well as the other triazoles, flu-
conazole and itraconazole. Major discrepancies were not enhanced with this method. If further
correlations of in vivo response to triazoles showbetween the two methods were uncommon and
were found most often for C. glabrata. With both that 24-h MIC readings correlate better with
outcome, then the colorimetric method will notmethods, the voriconazole endpoints were the
most clear-cut of the three triazoles. This could
reflect the ability of this new triazole to more
effectively inhibit yeasts when compared with the enhance in vitro susceptibility testing.
older triazoles.
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